PriceTargets.com logo

Jacobio Pharmaceuticals Group - JBPHF Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.30 As of 07/25/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for JBPHF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Jacobio Pharmaceuticals Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for JBPHF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for JBPHF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Jacobio Pharmaceuticals Group in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.30.

This chart shows the closing price for JBPHF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Jacobio Pharmaceuticals Group. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/5/2023The Goldman Sachs GroupDowngradeBuy ➝ Neutral
(Data available from 7/26/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/28/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/28/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/26/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.

Jacobio Pharmaceuticals Group

Jacobio Pharmaceuticals Group Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. The company's lead drug development programs include two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors comprising JAB-3312 and JAB-3068 for the treatment of esophageal cancer; JAB-8263, a small molecule inhibitor of BET family proteins regulating MYC transcription to treat various cancers; and JAB-21822, an oral small molecule targeting mutant KRAS G12C protein. It also develops JAB-BX102, a humanized inhibitory antibody against human CD73 for the treatment of PD-(L)1 resistant cancer; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, a tumor metabolic pathway for the treatment of solid tumors; and JAB-BX300, a molecule antibody targeting RAS pathway to treat pancreatic and other solid tumors with KRAS mutations. The company has a strategic collaboration with AbbVie Ireland Unlimited Company to develop and commercialize SHP2 inhibitors. The company was founded in 2015 and is headquartered in Beijing, China.
Read More

Today's Range

Now: $0.30
Low: $0.30
High: $0.30

50 Day Range

MA: $0.30
Low: $0.30
High: $0.30

52 Week Range

Now: $0.30
Low: $0.30
High: $0.30

Volume

N/A

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Jacobio Pharmaceuticals Group?

The following equities research analysts have issued stock ratings on Jacobio Pharmaceuticals Group in the last twelve months:
View the latest analyst ratings for JBPHF.

What is the current price target for Jacobio Pharmaceuticals Group?

0 Wall Street analysts have set twelve-month price targets for Jacobio Pharmaceuticals Group in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Jacobio Pharmaceuticals Group in the next year.
View the latest price targets for JBPHF.

What is the current consensus analyst rating for Jacobio Pharmaceuticals Group?

Jacobio Pharmaceuticals Group currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for JBPHF.

What other companies compete with Jacobio Pharmaceuticals Group?

Other companies that are similar to Jacobio Pharmaceuticals Group include 180 Life Sciences, 3SBio, 60 Degrees Pharmaceuticals, Abcam and Adocia. Learn More about companies similar to Jacobio Pharmaceuticals Group.

How do I contact Jacobio Pharmaceuticals Group's investor relations team?

Jacobio Pharmaceuticals Group's physical mailing address is Building F2, No. 88 Kechuang 6th Street Beijing Economic-Technological Development Area, Beijing, China. The company's listed phone number is 86-10-5631-5466. The official website for Jacobio Pharmaceuticals Group is www.jacobiopharma.com. Learn More about contacing Jacobio Pharmaceuticals Group investor relations.